@entity1072 ( @entity1072 ) is the most common @entity1778 in the western world and affects mainly elderly @entity1 . In current phase  III trials, standard treatment options were established that differ mainly based on the fitness and age of the @entity1 . The combination of @entity3118 , @entity786 , and the @entity2225 antibody rituximab (FCR) is recommended for young @entity1 without relevant comorbidity, while @entity11441 and rituximab (BR) should be favored for elderly (ca. >   65 years) fit individuals. @entity11441 plus ofatumumab is another option in this situation. @entity1 with major comorbidities should receive @entity5805 combined with @entity2225 antibody (obinutuzumab or ofatumumab). In 2014, several new compounds were approved for @entity1 with ultrahigh risk genetic factors (17p-, @entity876 mut) and for relapsed/refractory @entity1072 : both idelalisib and @entity6490 are orally bioavailable kinase inhibitors that block key regulators of central pathways. For both agents, very impressive data are available with regard to tolerability and efficacy that will change the treatment paradigm in @entity1072 . With @entity35360 , a direct apoptosis inducer is being developed that in early clinical trials produced high remission rates combined with good tolerability. Combinations and sequences of the "novel" compounds obinutuzumab, ofatumumab, idelalisib, @entity6490 , and @entity35360 will be studied in coming years in clinical trials in order to prolong remission duration and reduce side effects with the eventual aim of curing @entity1072 .

[ XXXX : current standards and novel approaches].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity11441 :: ('MESH:C001758', 'Chemical') :: ['Bendamustine', 'bendamustine'] @entity2225 :: ('54474', 'Gene') :: ['CD20'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'Chronic lymphocytic leukemia'] @entity5805 :: ('MESH:D002699', 'Chemical') :: ['chlorambucil'] @entity876 :: ('7157', 'Gene') :: ['TP53'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity35360 :: ('MESH:C579720', 'Chemical') :: ['ABT-199'] @entity6490 :: ('MESH:C551803', 'Chemical') :: ['ibrutinib']
@entity1072 :: (MESH:D015451,Disease) :: ['Chronic lymphocytic leukemia']
